Octanate (Human Coagulation Factor Viii)

Human coagulation factor VIII, the active ingredient in Octanate, is a factor VIII concentrate presented as a solution for injection for intravenous use. It treats hemophilia A and acquired factor VIII deficiency in patients requiring replacement therapy.

GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Octanate is a factor VIII concentrate used to address disorders of the intrinsic coagulation pathway.

Hemophilia A: restores clotting ability in patients with congenital factor VIII deficiency. Acquired factor VIII deficiency: provides replacement to control bleeding in patients with acquired deficiency or inhibitors. Surgical prophylaxis in hemophilia A: supplies factor VIII to prevent peri‑operative bleeding.

Octanate may be associated with infusion‑related and immune‑mediated reactions.

Common Side Effects: - Infusion site erythema or pain - Headache - Fever or chills - Nausea - Arthralgia - Mild hypertension

Serious or Rare Side Effects: - Development of inhibitory antibodies (inhibitors) - Anaphylactic or severe allergic reactions - Thromboembolic events - Severe hypertension - Hemolysis or renal impairment

Octanate should be used under specialist supervision with attention to potential complications.

Monitor for inhibitor development: regular testing for anti‑factor VIII antibodies. Assess bleeding history: evaluate severity and frequency of prior bleeds. Avoid in known hypersensitivity: do not administer to patients with documented allergy to factor VIII products. Use with caution in hepatic or renal impairment: adjust monitoring as needed. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanate may interact with other hemostatic agents, affecting clotting balance.

Major Interactions (Avoid): - Concurrent use of other factor VIII concentrates: may increase inhibitor risk. - Combination with bypassing agents (e.g., FEIBA): heightened thrombosis risk. - Co‑administration with high‑dose procoagulants (e.g., activated prothrombin complex concentrates): may precipitate clot formation.

Moderate Interactions (Monitor Closely): - Antifibrinolytics such as tranexamic acid: may enhance clot stability. - Immunosuppressants: may alter inhibitor development. - Vaccinations: monitor immune response when given near factor VIII infusion.